Verve Therapeutics Slides As Insider Purchases Lose Another US$65k [Yahoo! Finance]
Verve Therapeutics, Inc. (VERV)
Company Research
Source: Yahoo! Finance
buy price of US$6.26 over the last year may be disappointed by the recent 25% decrease in the stock. Insiders purchase with the hope of seeing their investments increase in value over time. However, due to recent losses, their initial investment is now only worth US$411.2k, which is not great. While insider transactions are not the most important thing when it comes to long-term investing, we do think it is perfectly logical to keep tabs on what insiders are doing. View our latest analysis for Verve Therapeutics The Last 12 Months Of Insider Transactions At Verve Therapeutics Over the last year, we can see that the biggest insider purchase was by President Andrew Ashe for US$476k worth of shares, at about US$6.26 per share. That means that even when the share price was higher than US$5.41 (the recent price), an insider wanted to purchase shares. It's very possible they regret the purchase, but it's more likely they are bullish about the company. To us, it's very important to c
Show less
Read more
Impact Snapshot
Event Time:
VERV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VERV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VERV alerts
High impacting Verve Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VERV
News
- Bronstein, Gewirtz & Grossman, LLC Encourages Verve Therapeutics, Inc. (VERV) Investors to Inquire about Securities InvestigationAccesswire
- Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Verve Therapeutics, Inc. (VERV) And Encourages Investors to Reach OutAccesswire
- VERV INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces an Investigation into Verve Therapeutics, Inc. and Encourages Investors to Contact the FirmAccesswire
- Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Verve Therapeutics, Inc. (NASDAQ: VERV) had its price target raised by analysts at Canaccord Genuity Group Inc. from $29.00 to $32.00. They now have a "buy" rating on the stock.MarketBeat
VERV
Earnings
- 11/5/24 - Beat
VERV
Sec Filings
- 12/4/24 - Form 4
- 12/3/24 - Form 4
- 11/18/24 - Form SC
- VERV's page on the SEC website